about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

Temple University School of Medicine news Temple University School of Medicine news Temple University School of Medicine news

OFFICE OF news communications

News Archive


December 16, 2011

CONTACT: Rebecca Harmon rebecca.harmon@tuhs.temple.edu



Physicians, residents, researchers, administrators, medical students, and media representatives witnessed the beginning of a new era in cancer research, treatment, and prevention at a press conference held December 15th in the lobby of Temple University School of Medicine’s Medical Education and Research Building.


They came to hear TUSM Dean and Health System President and CEO Larry R. Kaiser, MD, FACS, and Fox Chase Cancer Center President and CEO Michael V. Seiden, MD, PhD, announce an Affiliation Agreement that moves both institutions closer to bringing Fox Chase Cancer Center into the Temple family – marking a major milestone for two celebrated Philadelphia institutions that will enhance cancer research and patient care in the region, both immediately and for years to come.


“This affiliation creates a rich climate for life-changing cancer research and care by multiplying the value of the exceptional researchers and clinicians from two household names in Philadelphia medicine – Temple and Fox Chase,” Kaiser told the assembled reporters and guests. “Our new relationship will strengthen Philadelphia as a destination for patients searching for the most state-of-the-art treatments, and for clinicians and researchers dedicated to preventing and curing this difficult disease,” he noted.


Kaiser described how the new affiliation will exponentially increase the interaction opportunities between world-class scientists and clinicians, and will offer a level of excellence and expertise – combined with a cancer research network and clinical care infrastructure – that is second to none.


“Signing this definitive agreement provides both an inspirational and aspirational vision for Fox Chase, its patients, staff, and faculty in its quest to prevail over cancer,” added Seiden. “Our affiliation with Temple provides intellectual and capital resources to expand the breadth and depth of the clinical services we offer our patients, and helps bring cutting-edge clinical research to a larger fraction of patients who live in southeastern Pennsylvania and in New Jersey,” Seiden noted.


Following their prepared remarks, Kaiser and Seiden engaged in a Question-and-Answer session with reporters about the details and implications of the merger – including the considerable value that the consolidated cancer powerhouse brings to the region, the pride of having the Fox Chase name associated with the Temple “T,” the ways in which Fox Chase will expand its clinical space into Jeanes Hospital and onto the campus between the two institutions, and the imminent recruitment of new scientific and clinical staff to the Temple-Fox Chase cancer enterprise.


Said Kaiser in his closing remarks, “Temple’s newly-consolidated cancer hub will serve as a vital source of discovery, development, and delivery of the most effective approaches to cancer prevention, diagnosis, and treatment that will give patients the best of both worlds: access to the comprehensive treatments and innovative clinical-trials available at both Temple Cancer Center and Fox Chase Cancer Center.”